Parkinson’s drug effective in treating persistent depression
30 June 2025
A drug used for Parkinson’s disease has been shown to be effective in reducing the symptoms of difficult to treat depression, in a study led by the University of Oxford.
Construction begins on state-of-the-art research facility
27 June 2025
The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford’s mission to counter and constrain global health threats.
Oxford to lead new £50m MRC Centre to develop brain stimulation device-based therapies
27 June 2025
A new Medical Research Council Centre of Research Excellence (MRC CoRE) aims to develop brain stimulation devices to treat conditions such as Parkinson’s, dementia, stroke and childhood epilepsy.
How do vaccines reduce the risk of dementia?
26 June 2025
A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory syncytial virus (RSV) is associated with a 29% reduction in dementia risk in the following 18 months. The findings suggest a novel explanation for how vaccines produce this effect.
‘Single shot’ malaria vaccine delivery system could transform global immunisation
26 June 2025
Oxford researchers have developed programmable microcapsules to deliver vaccines in stages, potentially eliminating the need for booster shots and increasing immunisation coverage in hard-to-reach communities.
Associate Professor reaches new heights with the Thames Valley Air Ambulance
23 June 2025
David Metcalfe, Associate Professor of Emergency Medicine at Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), has begun a two-year secondment with Thames Valley Air Ambulance.
Alan Davidson Foundation renews funding for ground-breaking motor neuron disease research at Oxford
20 June 2025
As part of its renewed commitment, the Alan Davidson Foundation will continue to fund a full-time project manager to facilitate the ongoing coordination and growth of the ACORN study. The foundation is also contributing to the cost of a research fellow to support the next phase of the project.
Oxford academics awarded European Research Council Advanced Grants for cutting-edge research
19 June 2025
Seven researchers at the University of Oxford, including four from Medical Sciences, have been awarded Advanced Grants from the European Research Council, each worth up to €2.5 million over a period of five years.
Identification of a new metabolic axis underpinning cardiac dysfunction in diabetes
19 June 2025
A new publication from Department of Physiology, Anatomy and Genetics identifies a new metabolic axis which explains why the diabetic heart becomes fatty.
Oxford’s OrganOx is shortlisted for the MacRobert Award 2025
17 June 2025
The Royal Academy of Engineering has announced the finalists for the 2025 MacRobert Award, the longest running and most prestigious prize for UK engineering innovation.
King's Birthday Honours 2025
13 June 2025
Professor Andrew Carr has been recognised and celebrated in the 2025 King's Birthday Honours list.
Oxford researchers uncover a potential new therapeutic target for a hard-to-treat form of leukaemia
12 June 2025
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
Oxford strengthens global mindfulness research with £1 million gift
12 June 2025
The University of Oxford has announced a £1 million donation to advance the work of the Oxford Mindfulness Research Centre.
Intensive weight loss programme improves eating disorder symptoms in people with Type 2 Diabetes at risk of eating disorders, new study finds
11 June 2025
New study finds intensive diet programmes safely improve eating disorder symptoms in people with type 2 diabetes. Research published in The Lancet Psychiatry challenges assumptions about weight loss interventions for vulnerable patients, potentially expanding treatment options.
New consortium to make UK a world leader in AI drug discovery
10 June 2025
A new consortium, co-led by NDM researchers, has just been announced, aiming to make the UK a leader in artificial intelligence-driven drug discovery. The ‘OpenBind’ consortium will slash the cost of drug discovery and development by as much as £100 billion.
New research reveals druggable target arising from chromosomal rearrangement in aggressive leukaemia
10 June 2025
Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.
Oxford vaccine against deadly Nipah virus granted European Medicines Agency PRIME designation
9 June 2025
The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.
Malaria vaccine wins Galien Foundation prize for Best Public Sector Innovation
9 June 2025
The R21/Matrix-M malaria vaccine has received the Galien Foundation prize for Best Public Sector Innovation. Members of the Jenner Institute team, Prof Sir Adrian Hill, Mehreen Datoo and Lisa Stockdale were present during the Galien Foundation UK Forum & Awards Ceremony in London on 05 June 2025.
Study highlights effectiveness of neuromodulatory therapy on severe epileptic focal seizures
6 June 2025
A long-term clinical study has confirmed the effectiveness of a neuromodulatory treatment for severe focal seizures in both children and adults with drug-resistant epilepsy (DRE) and demonstrated the therapy’s lasting impact.
New research identifies key driver of inflammation in spondyloarthritis
5 June 2025
NDORMS researchers have identified a primary source of inflammatory IL-17 driving spondyloarthritis, paving the way for the development of targeted therapies to treat the condition.